🏛️ Verified NIH Record • Updated 2025-06-10

Tirzepatide for Obesity and Meth Use Disorder (NCT06745128)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: University of Texas Southwestern Medical Center

🩺 Plain-English Summary (8th-Grade Level)

This is an open-label pilot study to evaluate the feasibility and preliminary efficacy of using tirzepatide when prescribed for its United States (US) Food and Drug Administration (FDA)-approved weight-related indication in individuals with comorbid methamphetamine use disorder.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (11 items) and avoid the listed exclusions (17 items).

Location: UT Southwestern Medical Center — Dallas, Texas

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Current or recent use (within 3 months prior to consent) of other tirzepatide-containing products or any other GLP-1 receptor agonist
  • Current or recent use (within 30 days) of sulfonylureas, other concomitantly administered insulin secretagogue, or insulin
  • Current or recent use (within 3 months prior to consent) of other weight loss agents
  • Weight loss surgery within 12 months prior to consent
  • Current eating disorder per clinician evaluation
  • Personal or family history of Medullary Thyroid Carcinoma
  • History of Multiple Endocrine Neoplasia syndrome type 2
  • Known serious hypersensitivity (e.g., anaphylaxis, angioedema) to tirzepatide or any of the excipients in tirzepatide
  • History of angioedema or anaphylaxis with a GLP-1 receptor agonist
  • Current Stage 3 or higher Chronic Kidney Disease, defined as eGFR \<60 at Screening
  • Current inadequately controlled diabetes, defined as HbA1c \> 7.0 at Screening

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

  • UT Southwestern Medical Center — Dallas, Texas

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗